Stephen Poor

Stephen Poor

Company: Novartis

Job title: Director of Translational Biomarkers at NIBR


Reviewing the Key Lessons Learned from Phase 2 GA Trials 8:30 am

Review of lessons learned from our IVT complement Factor P inhibitor GA Phase 2 trial Data on how geographic atrophy is measured – the importance of patient level data vs summed data Fundus autofluorescence measure vs OCT measurements – functional outcomes including chart-based tests vs microperimetryRead more

day: Day Two

Panel Discussion Clinical Trial Design – Lessons Learned & Reflection on Preclinical Work 3:45 pm

What have we learned from the course of clinical trials? Can preclinical trials be better utilized for effective translation into the clinic Contemplating alternatives to BCVA & LLVARead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.